Amgen

Amgen selects Patheon as a 'strategic' manufacturing partner

Image: iStock/Jezperklauzen

The flexible manufacturing deal with Amgen is a departure from the standard transactional contract approach, according to Patheon.

The original paper showed how the obesity and insulin resistance pattern of hibernating grizzly bears may have implications in human diabetes

Bear-faced lie? Amgen retracts diabetes-obesity paper due to data manipulation

Research consortium looks to identify biomarkers for autism treatments

Research consortium looks to identify biomarkers for autism treatments

FDA offers guidance for running early-phase trials for gene, cell therapies

FDA offers guidance for running early-phase trials for gene, cell therapies

SAFC opens Tech Center in Singapore

Sigma-Aldrich opens doors to latest Singapore biopharma investment

WuXi to more than double US cell therapy manufacturing ops with new site

WuXi to more than double US cell therapy manufacturing ops with new site

Brian Cass, Huntingdon CEO

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

Big Pharma: outsourcing or investing in-house?

CMO use to grow despite Big Biopharma's in-house spend, say experts

Sponsors and CROs talk strategic alliances at PCT in Vienna, Austria

Oversight is key in sponsor-CRO partnerships say Pfizer and Amgen

Amgen invest in Singapore

Asian hub’s ambition attracts Amgen into Asia biomanufacture

More Amgen